Original Article
Brief Report
The HBV Drug Entecavir — Effects on HIV-1 Replication and Resistance
N Engl J Med 2007; 356:2614-2621June 21, 2007
- Abstract
Entecavir, a drug approved by the Food and Drug Administration for the treatment of chronic hepatitis B virus (HBV) infection, is not believed to inhibit replication of human immunodeficiency virus type 1 (HIV-1) at clinically relevant doses. We observed that entecavir led to a consistent 1-log10 decrease in HIV-1 RNA in three persons with HIV-1 and HBV coinfection, and we obtained supportive in vitro evidence that entecavir is a potent partial inhibitor of HIV-1 replication. Detailed analysis showed that in one of these patients, entecavir monotherapy led to an accumulation of HIV-1 variants with the lamivudine-resistant mutation, M184V. In vitro experiments showed that M184V confers resistance to entecavir. Until more is known about HIV-1–resistance patterns and their selection by entecavir, caution is needed with the use of entecavir in persons with HIV-1 and HBV coinfection who are not receiving fully suppressive antiretroviral regimens.
Media in This Article
Figure 1
Acute Decreases in Plasma Levels of HBV DNA and HIV-1 RNA with Entecavir Therapy.Figure 2
Inhibitory Effects of Entecavir on HIV-1 Infection In Vitro.Article Activity
- Article
Entecavir, an analogue of 2′-deoxyguanosine, is converted intracellularly to an active 5′-triphosphate form that inhibits hepatitis B virus (HBV) polymerase.1-3 Entecavir is approved by the Food and Drug Administration for the treatment of chronic hepatitis B infection. A previous study1 indicated that it has no clinically relevant activity against human immunodeficiency virus type 1 (HIV-1), and the package insert states that the concentration needed to inhibit replication by 50% (EC50) for HIV-1 is greater than 1 μM, which is higher than concentrations achieved in vivo with dosages used to treat chronic hepatitis B. Because of this selective activity against HBV,4-7 several treatment guidelines, including the U.S. Public Health Service guidelines, recommend entecavir for hepatitis B treatment in HIV-1–infected persons who do not meet criteria for HIV-1 treatment.8-11 Here, we report that entecavir has clinically relevant activity against HIV-1 and can select HIV-1 variants resistant to the widely used antiretroviral drugs lamivudine and emtricitabine.
Case Reports
Patient 1
Patient 1 is a 31-year-old white man with HIV-1 and HBV coinfection who tested seropositive for HIV-1 in 1990. In 2000, he received zidovudine, lamivudine, and nevirapine for the treatment of HIV-1. He took these drugs intermittently for less than 1 year. In February 2002, his CD4+ T-cell count was 596 cells per cubic millimeter, with a plasma HIV-1 RNA level of 14,602 copies per milliliter (Figure 1AFigure 1
Acute Decreases in Plasma Levels of HBV DNA and HIV-1 RNA with Entecavir Therapy.). His CD4+ T-cell counts and HIV-1 RNA levels remained stable for the next 4 years without therapy. In March 2006, he started entecavir therapy for chronic hepatitis B. At that time, his HIV-1 RNA level was 34,088 copies per milliliter and his CD4+ T-cell count was 574 cells per cubic millimeter.In the first 2 months while receiving entecavir, his HBV DNA level decreased from 9.60 to 3.95 log10 IU per milliliter. Simultaneously, the HIV-1 RNA level decreased by approximately 1 log10 to 2193 copies per milliliter, and his CD4+ T-cell count increased to 634 cells per cubic millimeter. His HIV-1 RNA level has slowly risen from its nadir and is 13,345 copies per milliliter after 12 months of therapy with the CD4+ T-cell count decreasing to 509 cells per cubic millimeter. During this same period, the HBV DNA level remained at its nadir.
Patient 2
Patient 2 is a 24-year-old man who received a diagnosis of HIV-1 infection in February 2003. Although acute HBV infection developed in March 2005, his HIV-1 infection did not meet the criteria for antiretroviral therapy. His HIV-1 RNA levels ranged from 40,000 to 60,000 copies per milliliter and his CD4+ T-cell counts were generally greater than 500 cells per cubic millimeter.
In February 2006, he began to receive entecavir for the treatment of chronic hepatitis B. After 1 month, the HIV-1 RNA level decreased 1.23 log10, from 40,273 to 2347 copies per milliliter (Figure 1B), and his CD4+ T-cell count rose from 490 to 568 cells per cubic millimeter. While he was receiving entecavir, his HBV DNA level decreased from approximately 9 to 5 log10 IU per milliliter. Given the concern for the activity of entecavir against HIV-1 and for the possible generation of drug-resistant HIV-1, his treatment was switched to tenofovir, emtricitabine, and efavirenz after 45 days of treatment with entecavir.
Patient 3
Patient 3 is a 46-year-old man with HIV-1 and HBV coinfection who became HIV-1–seropositive in the 1980s. In 1993, he received zidovudine monotherapy for an undetermined period of time followed by zidovudine plus lamivudine intermittently between 1997 and 2004. He was not fully compliant with this therapy. Before he received zidovudine plus lamivudine in 1996, his HIV-1 RNA level was 30,075 copies per milliliter and his CD4+ T-cell count was 375 cells per cubic millimeter. From September 2005 to February 2006, he received pegylated interferon alfa-2a to treat his chronic hepatitis B and had a poor response.
In August 2006, he began to receive entecavir monotherapy for chronic hepatitis B. When entecavir was initiated, he had an HIV-1 RNA level of 55,451 copies per milliliter and a CD4+ T-cell count of 399 cells per cubic millimeter. After 2 months of receiving entecavir, his HIV-1 RNA level decreased 0.85 log10 to 7797 copies per milliliter with a concomitant rise in his CD4+ T-cell count to 480 cells per cubic millimeter (Figure 1C). His HIV-1 RNA level has remained below baseline after 7 months of entecavir monotherapy. During this period, his HBV DNA level decreased from 6.63 to 1.99 log10 IU per milliliter.
Methods
Peripheral-Blood Samples
Peripheral blood was obtained from Patients 1 and 3 after they provided written informed consent. HIV-1 RNA was extracted from plasma and a segment of the pol gene was amplified by reverse-transcriptase polymerase chain reaction (RT-PCR), as described previously.12 The products were cloned, and multiple independent clones from each PCR reaction were sequenced. A maximum-likelihood phylogenetic tree was constructed by means of the PAUP program (Sinauer), as described previously.13 This study was approved by the institutional review board at Johns Hopkins University.
Phenotypic Analysis
Dose–response curves for inhibition of HIV-1 infection were generated in vitro by means of a previously described phenotypic assay.12 Briefly, recombinant CXCR4-tropic HIV-1 pseudoviruses were generated by cotransfecting HEK 293T cells with a plasmid containing the HIV-1 genome with a portion of envelope gene replaced by enhanced green fluorescent protein (pNL4-3-ΔE-GFP) and with a plasmid encoding the HIV-1 envelope (pCXCR4). Culture supernatants were collected, spun at 335×g, and filtered through a 0.22-μm membrane to clear cell debris. Virus was pelleted at 100,000×g for 2 hours at 4°C. Viral supernatants were standardized by means of p24 enzyme-linked immunosorbent assay (Beckman Coulter).
To obtain primary CD4+ T lymphoblasts for infection, peripheral-blood mononuclear cells from healthy donors were activated with phytohemagglutinin for 48 to 72 hours. CD4+ lymphoblasts were isolated with the use of Miltenyi Biotec beads and pretreated for 16 to 19 hours with increasing amounts of the indicated drugs before infection with standardized amounts of virus. The extent of infection was determined by quantifying the number of green fluorescent protein (GFP)-positive cells after 72 hours with the use of fluorescence-activated cell-sorter analysis. These experiments were repeated in triplicate with cells from three different healthy blood donors.
The M184V mutant plasmid was generated by site-directed mutagenesis (Stratagene) of pNL4-3-ΔE-GFP, and virus was made and standardized as above. To test patient-derived pol sequences for susceptibility to entecavir, a 1.5-kb pol sequence was amplified with the use of RT-PCR from four persons: Patients 1 and 3 in this study and two other HIV-1–infected persons who were not receiving entecavir (Patients 4 and 5, from the study by Bailey et al.).13 PCR products were cloned into pNL4-3-ΔE-GFP as previously described.12 The isolate from Patient 3 had the nonnucleoside reverse-transcriptase inhibitor resistance mutation K103N in HIV-1 reverse transcriptase. The isolate from Patient 4 had no drug-resistance mutations and the isolate from Patient 5 had the V108I and T215D mutations in reverse transcriptase.
Effect of Entecavir on Reverse Transcription
CXCR4-tropic recombinant HIV-1 pseudovirus was treated with DNase and used to infect CD4+ lymphoblasts from healthy donors in the presence or absence of entecavir at a concentration of 50 μM. Total DNA was isolated 8 and 24 hours after infection, and the products of reverse transcription were quantified by real-time PCR with the use of three separate sets of primers (see the Supplementary Appendix, available with the full text of this article at www.nejm.org).
Results
Inhibition of HIV-1 Replication In Vitro
To determine whether the observed in vivo reductions in HIV-1 RNA levels were due to the direct effects of entecavir on HIV-1 replication, we used a precise HIV-1 infectivity assay.12 This assay is related to commercial phenotypic assays,14 but it has single-cell sensitivity and uses primary CD4+ T cells rather than transformed cell lines. HIV-1 pseudoviruses carrying pol gene sequences from a reference HIV-1 isolate or from patient-derived isolates were used to infect CD4+ lymphoblasts in the presence of increasing concentrations of antiviral drugs. Entecavir potently inhibited infection by both the reference strain (a 50% inhibitory concentration [IC50] between 0.1 and 1 nM) and the wild-type pseudoviruses derived from Patient 1 (IC50, approximately 1 nM) (Figure 2AFigure 2
Inhibitory Effects of Entecavir on HIV-1 Infection In Vitro.). Although the pseudovirus derived from Patient 1 had a slightly reduced susceptibility to entecavir as compared with that of the reference strain, the ability of entecavir to inhibit infection at very low concentrations was still apparent. Three additional patient-derived isolates including that from Patient 3 were also tested in this system, and infection by all three was inhibited by entecavir with an IC50 consistently in the low nanomolar range (Figure 2B). The in vitro inhibition is consistent with the 1-log10 decrease in HIV-1 RNA observed in the patients. The IC50 of entecavir for HIV-1 is 100 to 1000 times lower than that of zidovudine in this system (approximately 0.2 μM). The IC50 of entecavir in vitro is below the plasma concentrations achieved in vivo at doses given for hepatitis B (maximal concentration, 28 nM).15 For all HIV-1 isolates tested, the dose–response curve for entecavir was atypical in that although the drug partially inhibited HIV-1 infection at very low concentrations, the anti–HIV-1 activity of entecavir reaches a plateau at drug concentrations in the low nanomolar range and concentrations above 10 nM do not cause increased inhibition (Figure 2A and 2B). In contrast, zidovudine shows higher levels of inhibition of HIV-1 replication with increasing concentrations (Figure 2A). The fact that the inhibitory activity of entecavir plateaus may explain why anti–HIV-1 activity was not detected with the use of conventional assays.
Because entecavir is a nucleoside analogue, we hypothesized that the observed anti–HIV-1 activity was due to inhibition of HIV-1 reverse transcriptase. To test this hypothesis, we used real-time PCR to quantify reverse transcripts in cells infected in the presence of entecavir. Entecavir decreased the levels of early, intermediate, and late reverse transcripts (Figure 3Figure 3
Inhibition of HIV-1 Infection by Entecavir at or before the Reverse-Transcription Step.), suggesting that it may inhibit HIV-1 replication at or before the reverse-transcription step.The M184V Mutant Virus
To determine whether drug-resistant HIV-1 variants were selected by entecavir, we cloned and sequenced HIV-1 RNA from the plasma of Patients 1 and 3 immediately before the initiation of entecavir therapy and at various time points after initiation of entecavir therapy (Figure 4AFigure 4
Selection for the M184V Mutation in HIV-1 Reverse Transcriptase in a Patient Receiving Entecavir.). When entecavir was initiated in Patient 1, none of 19 independent clones had mutations in HIV-1 pol known to confer resistance to anti–HIV-1 drugs. At 2, 4, and 6 months after initiation of entecavir therapy, 12%, 61%, and 96% of the clones, respectively, harbored the M184V mutation (Figure 4B). This mutation confers a high level of resistance to the anti–HIV-1 drugs lamivudine and emtricitabine.17-19 No other known resistance mutations were observed. The clinical genotype (HIV-1 Genotype, Quest Diagnostics Nichols Institute) obtained 6 months after the initiation of entecavir therapy confirmed the presence of the M184V mutation. By phylogenetic analysis (Figure 4C), the M184V mutants detected while the patient was receiving entecavir therapy showed greater divergence from the most recent common ancestor than did most of the wild-type sequences present before entecavir therapy. These results are consistent with the selection of M184V viruses by entecavir.In Patient 3, who had more extensive previous lamivudine therapy than Patient 1, no clones with the M184V mutation were detected at the time entecavir was started. After 7 months of entecavir therapy, only 1 of 175 clones had the M184V mutation. The only other known resistance mutation detected in this patient was the nonnucleoside reverse-transcriptase inhibitor resistance mutation K103N, which was present in all the clones before and after entecavir therapy. Taken together, these results indicated that entecavir can select the M184V mutation in some but not all patients.
Since entecavir can select the M184V mutation in vivo, we hypothesized that HIV-1 variants with the M184V mutation would be less susceptible to entecavir. The HIV-1 reference strain carrying the M184V mutation was resistant to entecavir (Figure 2C). In control experiments (Figure 2C), we showed that the same M184V mutant virus had markedly decreased susceptibility to lamivudine and the expected hypersusceptibility to zidovudine.17,18,20,21 A post-entecavir isolate from Patient 1 containing the M184V mutation behaved similarly (Figure 2D).
Discussion
This study shows that entecavir is a potent but partial inhibitor of HIV-1 replication in vitro and in vivo and that in some patients it can select for viruses bearing the M184V mutation, which confers high-level resistance to entecavir and to the widely used anti–HIV-1 drugs lamivudine and emtricitabine. These conclusions are supported by the temporal association of entecavir therapy with approximately 1-log10 reductions in HIV-1 RNA levels in vivo as well as in vitro studies showing inhibition of HIV-1 infectivity at clinically relevant concentrations. In addition, selection of M184V variants occurred in one patient who was receiving entecavir monotherapy, and in vitro data showed reduced activity of entecavir on M184V variants derived from this patient as well as from a laboratory strain.
These data have important implications for the treatment of hepatitis B in HIV-1–infected patients. Current guidelines recommend entecavir as the first-line treatment in persons with HIV-1 and HBV coinfection who do not require anti–HIV-1 therapy.8,9 Since this recommendation is predicated on the assumption that entecavir does not have activity against HIV-1, our data indicate that this recommendation should be reconsidered, especially since entecavir can select for the M184V mutation in some patients.
Our data contradict the findings of a previous report that entecavir does not have anti–HIV-1 activity at clinically relevant concentrations.1 That report used an assay described in 1989 by Weislow et al., which relies on cytopathic effects resulting from infection.22 We believe the quantitative infectivity assay we used has several advantages over previous assays that permit it to detect subtle anti–HIV-1 effects such as that shown by entecavir. First, the assay in our study permits a more direct measure of drug inhibition of early steps in HIV-1 replication from virus attachment through virus gene expression than older assays that used cell death as a surrogate measure of infection. Second, since the assay relies on a single round of infection, it permits the rapid and precise measurement of individual infection events without the complications introduced by multiple rounds of infection in an extended culture. A third advantage is that drug inhibition of HIV-1 replication is measured in primary CD4+ T lymphoblasts, which are the in vivo target cells of HIV-1, rather than in transformed cell lines, which may metabolize entecavir differently.
Further work is needed to understand why the M184V mutation emerged in one of the two patients who were studied in detail. It is unlikely that this patient was taking lamivudine, since it was not being prescribed to him at the time or in the recent past, and emergence of this mutation from lamivudine monotherapy typically occurs within weeks.23 Rather, the appearance of the M184V mutation probably reflects the fact that it decreases the anti–HIV-1 activity of entecavir. Selection of the M184V mutation in HIV-1 reverse transcriptase could be anticipated, since structural models show that the M184V mutation corresponds to the HBV pol mutation rtM204V,24 which decreases HBV susceptibility to entecavir.25 In both cases, the targeted methionine is in the YMDD motif at the active site.
The failure of the M184V mutation in HIV-1 reverse transcriptase to become dominant in Patient 3 may reflect the fact that this mutation has a well-known negative effect on viral fitness.26 In some patients, this reduction in fitness may outweigh the modest benefit conferred by entecavir resistance, since entecavir only partially inhibits HIV-1 replication. Thus, in some patients, selection for M184V may not occur or may occur very slowly.
It is also not known whether the M184V variants that appeared in Patient 1 after entecavir treatment were initially generated by exposure to a lamivudine-containing highly active antiretroviral therapy regimen several years earlier. Phylogenetic analysis suggests that the M184V variants evolved recently, most likely as a result of entecavir treatment. The appearance of M184V could also reflect the emergence of an archived variant from the latent reservoir,27 but in either case there is clear evidence that entecavir selected for this variant in Patient 1.
Several other questions are also raised by these observations. One question is whether control of HBV replication led to diminished lymphocyte activation or alterations in cytokine release that affected HIV-1 replication. Although these effects are theoretically possible, treatment of hepatitis B with adefovir dipivoxil in HIV-1–infected persons does not provide support for this hypothesis, since these patients had stable HIV-1 RNA levels despite decreases in HBV DNA levels.28 Although our data show that entecavir affects HIV-1 replication, we cannot rule out that such secondary effects may have contributed to the decrease in the HIV-1 RNA levels. Other questions include why the anti–HIV-1 activity of entecavir plateaus at low nanomolar concentrations, whether modifications of the compound could overcome the plateau effect, whether entecavir could play a clinically meaningful role as an antiretroviral agent for HIV-1, and whether entecavir selects for other HIV-1 drug-resistant mutants.
Entecavir, at doses used to treat chronic hepatitis B, is a potent partial inhibitor of HIV-1 replication and can select for the M184V resistance mutation in HIV-1 reverse transcriptase. Since the full extent of HIV-1 reverse-transcriptase mutations selected by entecavir monotherapy is not known, caution should be used in treating chronic hepatitis B with entecavir in HIV-1–infected patients who are not receiving fully suppressive antiretroviral regimens. Furthermore, these data underscore the importance of a careful study of agents with potential for anti–HIV-1 activity before licensure.
Supported by grants from the National Institutes of Health (R01AI060449, to Dr. Thio; and A143222 and A151178, to Dr. Siliciano).
The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, the Department of Defense, or the U.S. government.
No potential conflict of interest relevant to this article was reported.
We thank David Thomas for critical reading of this manuscript, Stuart Ray and Meghdad Rahdar for helpful discussions and advice, and our patients for their participation in this study.
Source Information
From the Departments of Pharmacology and Molecular Sciences (M.A.M., L.S., S.X., S.B., C.R.C., J.O.L.) and Medicine (B.L.J., T.P.B., Y.Z., M.W.-R., R.H., R.F.S., C.L.T.), Johns Hopkins University School of Medicine; and the Howard Hughes Medical Institute (R.F.S.) — both in Baltimore; and the Division of Infectious Diseases, Naval Medical Center, San Diego, San Diego, CA (B.H.).
Address reprint requests to Dr. Thio at the Department of Medicine, Johns Hopkins University School of Medicine, 1503 E. Jefferson St., Baltimore, MD 21231, or at cthio@jhmi.edu.
- References
References
1
Innaimo SF ,Seifer M ,Bisacchi GS ,Standring DN ,Zahler R ,Colonno RJ . Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997;41:1444-1448
Web of Science | Medline2
Marion PL ,Salazar FH ,Winters MA ,Colonno RJ . Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother 2002;46:82-88
CrossRef | Web of Science | Medline3
Yamanaka G ,Wilson T ,Innaimo S , et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999;43:190-193
Web of Science | Medline4
Doong SL ,Tsai CH ,Schinazi RF ,Liotta DC ,Cheng YC . Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991;88:8495-8499
CrossRef | Web of Science | Medline5
Heijtink RA ,De Wilde GA ,Kruining J , et al. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res 1993;21:141-153
CrossRef | Web of Science | Medline6
Ying C ,De Clercq E ,Neyts J . Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. J Viral Hepat 2000;7:79-83
CrossRef | Web of Science | Medline7
Karayiannis P . Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother 2003;51:761-785
CrossRef | Web of Science | Medline8
Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep 2004;53:1-112[Erratum, MMWR Morb Mortal Wkly Rep 2005;54:311.]
Medline9
Soriano V ,Miro JM ,Garcia-Samaniego J , et al. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J Viral Hepat 2004;11:2-17
CrossRef | Web of Science | Medline10
Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda, MD: Department of Health and Human Services, 2006. (Accessed May 25, 2007, at http://AIDSinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.)
11
Rathbun RC ,Lockhart SM ,Stephens JR . Current HIV treatment guidelines -- an overview. Curr Pharm Des 2006;12:1045-1063
CrossRef | Web of Science | Medline12
Zhang H ,Zhou Y ,Alcock C , et al. Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol 2004;78:1718-1729
CrossRef | Web of Science | Medline13
Bailey JR ,Sedaghat AR ,Kieffer T , et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 2006;80:6441-6457
CrossRef | Web of Science | Medline14
Petropoulos CJ ,Parkin NT ,Limoli KL , et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44:920-928
CrossRef | Web of Science | Medline15
Sims KA ,Woodland AM . Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection. Pharmacotherapy 2006;26:1745-1757
CrossRef | Web of Science | Medline16
Zack JA ,Arrigo SJ ,Weitsman SR ,Go AS ,Haislip A ,Chen IS . HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990;61:213-222
CrossRef | Web of Science | Medline17
Schinazi RF ,Lloyd RM Jr ,Nguyen MH , et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993;37:875-881
Web of Science | Medline18
Tisdale M ,Kemp SD ,Parry NR ,Larder BA . Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 1993;90:5653-5656
CrossRef | Web of Science | Medline19
Gao Q ,Gu Z ,Parniak MA , et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993;37:1390-1392
Web of Science | Medline20
Gallant JE ,Gerondelis PZ ,Wainberg MA , et al. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir Ther 2003;8:489-506
Web of Science | Medline21
Boyer PL ,Sarafianos SG ,Arnold E ,Hughes SH . The M184V mutation reduces the selective excision of zidovudine 5′-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. J Virol 2002;76:3248-3256
CrossRef | Web of Science | Medline22
Weislow OS ,Kiser R ,Fine DL ,Bader J ,Shoemaker RH ,Boyd MR . New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst 1989;81:577-586[Erratum, J Natl Cancer Inst 1989;81:963.]
CrossRef | Web of Science | Medline23
Schuurman R ,Nijhuis M ,van Leeuwen R , et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-1419
CrossRef | Web of Science | Medline24
Bartholomeusz A ,Tehan BG ,Chalmers DK . Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther 2004;9:149-160
Web of Science | Medline25
Levine S ,Hernandez D ,Yamanaka G , et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002;46:2525-2532
CrossRef | Web of Science | Medline26
Back NKT ,Nijhuis M ,Keulen W , et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996;15:4040-4049
Web of Science | Medline27
Ruff CT ,Ray SC ,Kwon P , et al. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 2002;76:9481-9492
CrossRef | Web of Science | Medline28
Sheldon JA ,Corral A ,Rodes B , et al. Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS 2005;19:2036-2038
CrossRef | Web of Science | Medline
- Citing Articles (87)
Citing Articles
1
Anders Boyd, Pierre-Marie Girard, Karine Lacombe. (2012) Consequences of persistent HBV infection in HIV: the double-edged sword of nucleos(t)ide analogs. Future Virology 7:2, 139-148
CrossRef2
Henry Lik-Yuen Chan, Vincent Wai-Sun Wong. 2012. Hepatitis B. , 540-563.
CrossRef3
Marie-Louise Vachon, Ponni Perumalswami, Douglas T. Dieterich. 2011. Hepatobiliary Manifestations of Human Immunodeficiency Virus. , 1060-1082.
CrossRef4
Gillian M. Keating. (2011) Entecavir. Drugs 71:18, 2511-2529
CrossRef5
Z. Plaza, V. Soriano, M. d. M. Gonzalez, F. A. Di Lello, J. Macias, P. Labarga, J. A. Pineda, E. Poveda. (2011) Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients. Journal of Antimicrobial Chemotherapy 66:12, 2838-2842
CrossRef6
Myron J. Tong, Calvin Q. Pan, Hie-Won Hann, Kris V. Kowdley, Steven-Huy B. Han, Albert D. Min, Truong-Sinh Leduc. (2011) The Management of Chronic Hepatitis B in Asian Americans. Digestive Diseases and Sciences 56:11, 3143-3162
CrossRef7
Piero L. Almasio, Antonio Craxì. (2011) Management of hepatitis B virus infection in the underprivileged world. Liver International 31:6, 749-750
CrossRef8
I. Kinde, J. Wu, N. Papadopoulos, K. W. Kinzler, B. Vogelstein. (2011) Detection and quantification of rare mutations with massively parallel sequencing. Proceedings of the National Academy of Sciences 108:23, 9530-9535
CrossRef9
Irene N Rapti, Stephanos J Hadziyannis. (2011) Treatment of special populations with chronic hepatitis B infection. Expert Review of Gastroenterology & Hepatology 5:3, 323-339
CrossRef10
Marion G. Peters, Vincent Soriano. 2011. HIV and the Liver. , 438-451.
CrossRef11
Akahito Sako, Hideo Yasunaga, Hiromasa Horiguchi, Hideki Hashimoto, Naohiko Masaki, Shinya Matsuda. (2011) Acute hepatitis B in Japan: Incidence, clinical practices and health policy. Hepatology Research 41:1, 39-45
CrossRef12
(2011) Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-infected Koreans. Infection and Chemotherapy 43:2, 89
CrossRef13
Erik De Clercq. 2010. HIV Reverse Transcriptase Inhibitors. .
CrossRef14
Antonin Holý, Erik De Clercq. 2010. Anti-DNA Virus Agents. .
CrossRef15
Hank S. Wang, Steven-Huy B. Han. (2010) Management of Hepatitis B in Special Patient Populations. Clinics in Liver Disease 14:3, 505-520
CrossRef16
Valerianna K. Amorosa. (2010) New Frontiers of HCV Therapy in HIV/HCV Co-infection. Current HIV/AIDS Reports 7:3, 117-126
CrossRef17
C. S. Coffin, P. G. Stock, L. M. Dove, C. L. Berg, N. N. Nissen, M. P. Curry, M. Ragni, F. G. Regenstein, K. E. Sherman, M. E. Roland, N. A. Terrault. (2010) Virologic and Clinical Outcomes of Hepatitis B Virus Infection in HIV-HBV Coinfected Transplant Recipients. American Journal of Transplantation 10:5, 1268-1275
CrossRef18
Markus Peck-Radosavljevic, Johann Deutsch, Peter Ferenci, Ivo Graziadei, Harald Hofer, Heidemarie Holzmann, Wolf-Dietrich Huber, Herman Laferl, Andreas Maieron, Rudolf Stauber, Wolfgang Vogel. (2010) 4. Österreichischer Konsensusbericht zur Diagnose und Therapie der Hepatitis B 2009. Wiener klinische Wochenschrift 122:9-10, 280-302
CrossRef19
Alexander Monto, Robert T Schooley, Jennifer C Lai, Mark S Sulkowski, Raymond T Chung, Jean-Michel Pawlotsky, John G McHutchison, Ira M Jacobson. (2010) Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop. The American Journal of Gastroenterology 105:5, 989-1004
CrossRef20
Ester Lopez-Suñé, Montse Tuset, Montse Laguno, Asunción Moreno, José M. Miró. (2010) Características de los fármacos antivíricos activos frente al virus de la hepatitis y el virus de la influenza: actualización 2009. Enfermedades Infecciosas y Microbiología Clínica 28:4, 253.e1-253.e17
CrossRef21
L. Martin-Carbonero, V. Soriano. (2010) New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients. Journal of Antimicrobial Chemotherapy 65:3, 379-382
CrossRef22
Kenneth E. Sherman, Vincent Soriano, Raymond T. Chung. (2010) Human immunodeficiency virus and liver disease: Conference proceedings. Hepatology 51:3, 1046-1054
CrossRef23
Gregory J Dore, Vicente Soriano, Jürgen Rockstroh, Bernd Kupfer, Ellen Tedaldi, Lars Peters, Jacqueline Neuhaus, Massimo Puoti, Marina B Klein, Amanda Mocroft, Bonaventura Clotet, Jens D Lundgren. (2010) Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS 24:6, 857-865
CrossRef24
Mashu Aizawa, Akihito Tsubota, Kiyotaka Fujise, Tetsuro Kato, Mitsuo Sakamoto, Toshifumi Ohkusa, Hisao Tajiri. (2010) Highly active antiretroviral therapy improved persistent lamivudine-resistant viremia in acute hepatitis B virus genotype Ae infection with coinfection of human immunodeficiency virus. Hepatology Research 40:2, 229-235
CrossRef25
Moira A McMahon, Janet D Siliciano, Rahul M Kohli, Robert F Siliciano. (2010) Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs. AIDS 24:2, 319-323
CrossRef26
Akiyoshi Kinoshita, Gou Kobayashi, Tsunekazu Oikawa, Chisato Saeki, Yoshifumi Masui, Hirohiko Kobayashi, Nao Fushiya, Shunichi Sakabe, Norimasa Kijima, Yasu Onoda, Yuji Kuniyasu, Yoshinari Miyakwa, Hisato Nakajima, Hisao Tajiri. (2010) A case of acute hepatitis B associated with secondary syphilis. Kanzo 51:4, 163-168
CrossRef27
K. Lacombe, J. Bottero, M. Lemoine, A. Boyd, P. M. Girard. (2010) HIV/hepatitis B virus co-infection: current challenges and new strategies. Journal of Antimicrobial Chemotherapy 65:1, 10-17
CrossRef28
Vincent Soriano, Eugenia Vispo, Pablo Labarga, Jose Medrano, Pablo Barreiro. (2010) Viral hepatitis and HIV co-infection. Antiviral Research 85:1, 303-315
CrossRef29
Jorge L. Herrera. 2010. Antiviral Therapy for Hepatitis B. , 113-118.
CrossRef30
G Brook, J Main, M Nelson, S Bhagani, E Wilkins, C Leen, M Fisher, Y Gilleece, R Gilson, A Freedman, R Kulasegaram, K Agarwal, C Sabin, C Deacon-Adams, . (2010) British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Medicine 11:1, 1-30
CrossRef31
Christoph Eisenbach, Uta Merle, Wolfgang Stremmel, Jens Encke. (2009) Liver transplantation in HIV-positive patients. Clinical Transplantation 23, 68-74
CrossRef32
Moira A McMahon, Lin Shen, Robert F Siliciano. (2009) New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo. Current Opinion in Infectious Diseases 22:6, 574-582
CrossRef33
Waka Ohishi, Kazuaki Chayama. (2009) Current treatment for chronic hepatitis B in Japan. Clinical Journal of Gastroenterology 2:5, 325-330
CrossRef34
Melissa Osborn. (2009) Hepatitis B in HIV: Available treatment options and approach to therapy. Current Infectious Disease Reports 11:5, 407-413
CrossRef35
Marie-Louise Vachon, Douglas T. Dieterich. (2009) HIV and coinfected patients. Current Hepatitis Reports 8:3, 103-110
CrossRef36
David M Iser, Sharon R Lewin. (2009) Future directions in the treatment of HIV–HBV coinfection. HIV Therapy 3:4, 405-415
CrossRef37
Lesley J. Scott, Gillian M. Keating. (2009) Entecavir. Drugs 69:8, 1003-1033
CrossRef38
Chloe L. Thio. (2009) Hepatitis B and human immunodeficiency virus coinfection. Hepatology 49:S5, S138-S145
CrossRef39
Curtis L. Cooper, Edward Mills, Ben O. Wabwire, Nathan Ford, Peter Olupot-Olupot. (2009) Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa. International Journal of Infectious Diseases 13:3, 302-306
CrossRef40
Martin Potter, Marina B Klein. (2009) Co-infections and co-therapies: treatment of HIV in the presence of hepatitis C and hepatitis B. HIV Therapy 3:2, 189-207
CrossRef41
Jerome Deval. (2009) Antimicrobial Strategies. Drugs 69:2, 151-166
CrossRef42
Cihan Yurdaydin. (2008) Entecavir: a step forward in combating hepatitis B disease. Expert Opinion on Pharmacotherapy 9:17, 3095-3109
CrossRef43
Emmet B. Keeffe, Douglas T. Dieterich, Steven-Huy B. Han, Ira M. Jacobson, Paul Martin, Eugene R. Schiff, Hillel Tobias. (2008) A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update. Clinical Gastroenterology and Hepatology 6:12, 1315-1341
CrossRef44
N. K. GUPTA, J. H. LEWIS. (2008) Review article: the use of potentially hepatotoxic drugs in patients with liver disease. Alimentary Pharmacology & Therapeutics 28:9, 1021-1041
CrossRef45
Dienstag, Jules L., . (2008) Hepatitis B Virus Infection. New England Journal of Medicine 359:14, 1486-1500
Full Text46
Pin-Nan Cheng, Ting-Tsung Chang. (2008) Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients. Expert Review of Anti-infective Therapy 6:5, 569-579
CrossRef47
Erik De Clercq. (2008) Emerging antiviral drugs. Expert Opinion on Emerging Drugs 13:3, 393-416
CrossRef48
Rong-Nan Chien. (2008) Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B. Hepatology International 2:3, 296-303
CrossRef49
Bulent Degertekin, Anna SF Lok. (2008) Update on viral hepatitis: 2007. Current Opinion in Internal Medicine 7:4, 332-337
CrossRef50
Ellen Kitchell, Mamta K. Jain. (2008) Evaluation and treatment of the patient coinfected with hepatitis B and HIV. Current HIV/AIDS Reports 5:3, 103-111
CrossRef51
Koji Fukushima, Yoshiyuki Ueno, Jun Inoue, Yuta Wakui, Noriyuki Obara, Osamu Kimura, Osamu Kido, Yu Nakagome, Eiji Kakazu, Yasunori Matsuda, Takayuki Kogure, Yasuteru Kondo, Futoshi Nagasaki, Yoko Yamagiwa, Yugo Ashino, Tooru Shimosegawa. (2008) A case of HIV co-infected with hepatitis B virus precorecore deletion mutant treated by entecavir. Hepatology Research 38:8, 842-846
CrossRef52
Vincent Soriano, Massimo Puoti, Marion Peters, Yves Benhamou, Mark Sulkowski, Fabien Zoulim, Stefan Mauss, Juergen Rockstroh. (2008) Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 22:12, 1399-1410
CrossRef53
Megan Crane, Gail Matthews, Sharon R Lewin. (2008) Hepatitis virus immune restoration disease of the liver. Current Opinion in HIV and AIDS 3:4, 446-452
CrossRef54
Lin Shen, Susan Peterson, Ahmad R Sedaghat, Moira A McMahon, Marc Callender, Haili Zhang, Yan Zhou, Eleanor Pitt, Karen S Anderson, Edward P Acosta, Robert F Siliciano. (2008) Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nature Medicine 14:7, 762-766
CrossRef55
Michael Nassal. (2008) Hepatitis B viruses: Reverse transcription a different way. Virus Research 134:1-2, 235-249
CrossRef56
Nancy Leung. (2008) Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatology International 2:2, 163-178
CrossRef57
Aimi Kanada, Tetsuo Takehara, Kazuyoshi Ohkawa, Michio Kato, Tomohide Tatsumi, Takuya Miyagi, Ryotaro Sakamori, Shinjiro Yamaguchi, Akio Uemura, Keisuke Kohga, Akira Sasakawa, Hayato Hikita, Kiyomi Kawamura, Tatsuya Kanto, Naoki Hiramatsu, Norio Hayashi. (2008) Early emergence of entecavir-resistant hepatitis B virus in a patient with hepatitis B virus/human immunodeficiency virus coinfection. Hepatology Research 38:6, 622-628
CrossRef58
Joseph J. Eron. (2008) Managing Antiretroviral Therapy: Changing Regimens, Resistance Testing, and the Risks from Structured Treatment Interruptions. The Journal of Infectious Diseases 197:s3, S261-S271
CrossRef59
Vincent Soriano, Eugenia Vispo, Marcelle Bottecchia, Julie Sheldon, Paula Tuma, Javier Garcia-Samaniego, Pablo Barreiro. (2008) Management of hepatitis B virus co-infection on and off antiretroviral therapy. Current HIV/AIDS Reports 5:2, 86-93
CrossRef60
Stephen Barclay, Stanislas Pol, David Mutimer, Yves Benhamou, Peter R. Mills, Peter C. Hayes, Sheila Cameron, William Carman. (2008) Erratum to ‘The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting’ [J. Clin. Virol. 41 (4) 2008 243–254]. Journal of Clinical Virology 42:1, 104-115
CrossRef61
José Luis Calleja, Beatriz Peñas. (2008) Entecavir. Enfermedades Infecciosas y Microbiología Clínica 26, 39-48
CrossRef62
David M Iser, Joseph J Sasadeusz. (2008) Current treatment of HIV/hepatitis B virus coinfection. Journal of Gastroenterology and Hepatology 23:5, 699-706
CrossRef63
Julie Sheldon, Rui Sarmento e Castro, Vicente Soriano. (2008) Resistencias en el virus de la hepatitis B. Enfermedades Infecciosas y Microbiología Clínica 26, 49-55
CrossRef64
Pablo Barreiro, Luz Martín-Carbonero, Javier García-Samaniego. (2008) Hepatitis B en pacientes con infección por el virus de la inmunodeficiencia humana. Enfermedades Infecciosas y Microbiología Clínica 26, 71-79
CrossRef65
Daniel S Pratt. (2008) Liver disorders. Current Opinion in Gastroenterology 24:3, 265-268
CrossRef66
Martin R. Jakobsen, Hanne Arildsen, Henrik B. Krarup, Martin Tolstrup, Lars Østergaard, Alex L. Laursen. (2008) Entecavir Therapy Induces de Novo HIV Reverse‐Transcriptase M184V Mutation in an Antiretroviral Therapy–Naive Patient. Clinical Infectious Diseases 46:9, e88-e91
CrossRef67
Bulent Degertekin, Anna SF Lok. (2008) Update on viral hepatitis: 2007. Current Opinion in Gastroenterology 24:3, 306-311
CrossRef68
Joe Sasadeusz, Jennifer Audsley, Anne Mijch, Rachel Baden, Jose Caro, Hermeyone Hunter, Gail Matthews, Moira A McMahon, Susan A Olender, Robert F Siliciano, Sharon R Lewin, Chloe L Thio. (2008) The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS 22:8, 947-955
CrossRef69
Stephen Barclay, Stanislas Pol, David Mutimer, Yves Benhamou, Peter R. Mills, Peter C. Hayes, Sheila Cameron, William Cameron. (2008) The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting. Journal of Clinical Virology 41:4, 243-254
CrossRef70
Vincent Soriano, Eugenia Vispo, Pablo Labarga, Pablo Barreiro. (2008) A low antiretroviral activity of the antihepatitis B drug entecavir may be enough to select for M184V in HIV-1. AIDS 22:7, 911-912
CrossRef71
Stefan Mauss, Heiner Wedemeyer. (2008) Treatment of chronic hepatitis B and the implications of viral resistance to therapy. Expert Review of Anti-infective Therapy 6:2, 191-199
CrossRef72
José M. Sánchez-Tapias. (2008) Fármacos para el tratamiento de la hepatitis B crónica. Gastroenterología y Hepatología 31:3, 120-128
CrossRef73
Mark S. Sulkowski. (2008) Viral hepatitis and HIV coinfection. Journal of Hepatology 48:2, 353-367
CrossRef74
JK Rockstroh, S Bhagani, Y Benhamou, R Bruno, S Mauss, L Peters, M Puoti, V Soriano, C Tural, . (2008) European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Medicine 9:2, 82-88
CrossRef75
Hussien Elsiesy, Douglas Dieterich. (2008) Dual therapy for chronic hepatitis B virus. Current Hepatitis Reports 7:1, 33-39
CrossRef76
Marcelle Bottecchia, Javier Garcia-Samaniego, Vincent Soriano. (2008) The implications of antiviral drugs with activity against hepatitis B virus and HIV. Current Opinion in Internal Medicine 7:1, 57-64
CrossRef77
Norie Yamada, Hiroshi Yotsuyanagi, Yu Koitabashi, Yoshihiko Nagase, Chiaki Okuse, Kiyomi Yasuda, Michihiro Suzuki, Kazuhiko Koike, Shiro Iino, Fumio Itoh. (2008) Epidemiology and clinical features of acute hepatitis B in Japan -Analysis with an emphasis on genotype A HBV-. Kanzo 49:12, 553-559
CrossRef78
Charles Flexner. (2007) HIV drug development: the next 25 years. Nature Reviews Drug Discovery 6:12, 959-966
CrossRef79
Joe Sasadeusz. (2007) The anti-HIV antiviral activity of entecavir: The loss of a trusted friend?. Journal of Hepatology 47:6, 872-874
CrossRef80
Mamta K Jain, Cindy L Zoellner. (2007) Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naïve patient treated for chronic HBV. AIDS 21:17, 2365-2366
CrossRef81
Srinivas Cheruvu, Kristen Marks, Andrew H. Talal. (2007) Understanding the Pathogenesis and Management of Hepatitis B/HIV and Hepatitis B/Hepatitis C Virus Coinfection. Clinics in Liver Disease 11:4, 917-943
CrossRef82
Martin Vogel, Jürgen Rockstroh. (2007) Highlights of the Third International Workshop on HIV and Hepatitis Coinfection. Expert Review of Anti-infective Therapy 5:5, 769-771
CrossRef83
Vincent Soriano, Julie Sheldon, Pilar García-Gasco, Eugenia Vispo. (2007) Lack of anti-HIV activity of entecavir in an HIV patient coinfected with hepatitis B and delta viruses. AIDS 21:16, 2253-2254
CrossRef84
A. Goede. (2007) Effect van entecavir op HIV-1-replicatie en resistentie. MFM 45:10, 289-290
CrossRef85
Martin Vogel, Jürgen Rockstroh. (2007) Highlights of the 3rd International Workshop on HIV and Hepatitis Coinfection. Future Virology 2:5, 437-439
CrossRef86
Hussien Elsiesy, Douglas Dieterich. (2007) Viral hepatitis in patients with HIV infection. Current Hepatitis Reports 6:3, 103-113
CrossRef87
Hirsch, Martin S., . (2007) Entecavir Surprise. New England Journal of Medicine 356:25, 2641-2643
Full Text
